A citation-based method for searching scientific literature

Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Lancet 2019
Times Cited: 916



Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Times Cited: 2852




List of shared articles



Times cited

A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.
Laura K Triantafylidis, Chelsea E Hawley, Christopher Fagbote, Jiahua Li, Nicole Genovese, Julie M Paik. J Pharm Pract 2021
5


Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Nobumichi Saito, Tomohiko Kanaoka, Hiroyuki Sakai, Takayuki Furuki, Tomoya Umezono, Shun Ito, Daisuke Suzuki,[...]. Diabetes Technol Ther 2021
1

Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Kåre I Birkeland, Johan Bodegard, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack,[...]. Diabetes Obes Metab 2021
8

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
Davide Margonato, Giuseppe Galati, Simone Mazzetti, Rosa Cannistraci, Gianluca Perseghin, Alberto Margonato, Andrea Mortara. Heart Fail Rev 2021
5

Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
Taufiq Salahuddin, Vanessa Richardson, Demetria M McNeal, Kamal Henderson, Paul L Hess, Sridharan Raghavan, David R Saxon, Javier A Valle, Stephen W Waldo, P Michael Ho,[...]. Diabetes Obes Metab 2021
0


An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
Jie Yu, Zien Zhou, Kenneth W Mahaffey, David R Matthews, Brendon L Neuen, Hiddo J L Heerspink, Meg J Jardine, JingWei Li, Vlado Perkovic, Bruce Neal,[...]. Int J Cardiol 2021
3

Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.
Adriana Marton, Tatsuroh Kaneko, Jean-Paul Kovalik, Atsutaka Yasui, Akira Nishiyama, Kento Kitada, Jens Titze. Nat Rev Nephrol 2021
13


Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
51

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Pardeep S Jhund, Scott D Solomon, Kieran F Docherty, Hiddo J L Heerspink, Inder S Anand, Michael Böhm, Vijay Chopra, Rudolf A de Boer, Akshay S Desai, Junbo Ge,[...]. Circulation 2021
31





Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
1


Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
7

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
83

Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Husam M Salah, Subhi J Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L Mehta, J Paul Mounsey, Stephen J Greene, Darren K McGuire, Renato D Lopes,[...]. Am Heart J 2021
13

Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.
Thomas A Zelniker, David A Morrow, Ofri Mosenzon, Erica L Goodrich, Petr Jarolim, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John Wilding,[...]. Eur J Heart Fail 2021
5

SGLT2-inhibitors; more than just glycosuria and diuresis.
Amir Fathi, Keeran Vickneson, Jagdeep S Singh. Heart Fail Rev 2021
3

How Diabetes and Heart Failure Modulate Each Other and Condition Management.
Varinder Kaur Randhawa, Savita Dhanvantari, Kim A Connelly. Can J Cardiol 2021
0

Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus.
Eirini Papadopoulou, Marieta P Theodorakopoulou, Charalampos Loutradis, Georgios Tzanis, Glykeria Tzatzagou, Kalliopi Kotsa, Ioanna Zografou, Apostolos Tsapas, Asterios Karagiannis, Pantelis Sarafidis. Am J Hypertens 2021
0


Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Chintan V Dave, Seoyoung C Kim, Allison B Goldfine, Robert J Glynn, Angela Tong, Elisabetta Patorno. Circulation 2021
3

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial.
Rosalie A Scholtes, Marcel H A Muskiet, Michiel J B van Baar, Anne C Hesp, Peter J Greasley, Cecilia Karlsson, Ann Hammarstedt, Niki Arya, Daniël H van Raalte, Hiddo J L Heerspink. Diabetes Care 2021
12

Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose-lowering agents: A population-based community study from the Shizuoka Kokuho database.
Shun Kohsaka, Hiraku Kumamaru, Shiori Nishimura, Satoshi Shoji, Eiji Nakatani, Nao Ichihara, Hiroyuki Yamamoto, Yoshiki Miyachi, Hiroaki Miyata. J Diabetes Investig 2021
1

Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial.
Ryotaro Bouchi, Noriyuki Sonoda, Jun Itoh, Yasuhiro Ono, Tatsuya Fukuda, Takato Takeuchi, Junji Kishimoto, Tetsuya Yamada, Yoshihiro Ogawa. Endocr J 2021
0

Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy.
Lin Wang, Yin Cai, Liguo Jian, Chi Wai Cheung, Liangqing Zhang, Zhengyuan Xia. Cardiovasc Diabetol 2021
4

Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.
Julius L Katzmann, Amy M Mason, Winfried März, Marcus E Kleber, Alexander Niessner, Matthias Blüher, Thimoteus Speer, Ulrich Laufs. Clin Pharmacol Ther 2021
0

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Matthias Rau, Kirsten Thiele, Niels-Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P Keszei, Michael Böhm, Nikolaus Marx, Michael Lehrke. Cardiovasc Diabetol 2021
4

Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis.
Kai Jiang, Yue Xu, Dandan Wang, Feng Chen, Zizhuo Tu, Jie Qian, Sheng Xu, Yixiang Xu, John Hwa, Jian Li,[...]. Protein Cell 2021
4


Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
Gábor Sütő, Gergő A Molnár, Gyorgy Rokszin, Ibolya Fábián, Zoltan Kiss, Zoltán Szekanecz, Gyula Poór, György Jermendy, Peter Kempler, István Wittmann. BMJ Open Diabetes Res Care 2021
2

Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
Elisabetta Patorno, Ajinkya Pawar, Lily G Bessette, Dae H Kim, Chintan Dave, Robert J Glynn, Medha N Munshi, Sebastian Schneeweiss, Deborah J Wexler, Seoyoung C Kim. Diabetes Care 2021
3

SGLT2 inhibitors: a narrative review of efficacy and safety.
Donald S Nelinson, Jose M Sosa, Robert J Chilton. J Osteopath Med 2021
0


The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
Michelle L O'Donoghue, Eri T Kato, Ofri Mosenzon, Sabina A Murphy, Avivit Cahn, Marisol Herrera, Tsvetalina Tankova, Alena Šmahelová, Piera Merlini, Ingrid Gause-Nilsson,[...]. Diabetologia 2021
0

Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
Edimar Alcides Bocchi, Andréa Biolo, Lidia Zytynski Moura, José Albuquerque Figueiredo Neto, Carlos Eduardo Lucena Montenegro, Denilson Campos de Albuquerque. Arq Bras Cardiol 2021
0

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.
Jamie L Benham, Jane E Booth, Ronald J Sigal, Stella S Daskalopoulou, Alexander A Leung, Doreen M Rabi. Int J Cardiol Heart Vasc 2021
0

Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin.
Ricardo Fontes-Carvalho, Diogo Santos-Ferreira, Itamar Raz, Nikolaus Marx, Frank Ruschitzka, Francesco Cosentino. Eur J Prev Cardiol 2021
0

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
David Z I Cherney, Bernard Charbonnel, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard Pratley, Weichung J Shih, Robert Frederich, Mario Maldonado, Annpey Pong,[...]. Diabetologia 2021
7

Evolution and Outcomes of Premature Coronary Artery Disease.
Cara Lea Smith, Matthew Seigerman, Srinath Adusumalli, Jay Giri, Paul N Fiorilli, Daniel M Kolansky, Taisei Kobayashi. Curr Cardiol Rep 2021
0

Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis.
Fotios Barkas, Sebastian Filippas Ntekouan, Evangelos Liberopoulos, Theodosios Filippatos, Haralampos Milionis. J Stroke Cerebrovasc Dis 2021
2

Hypertension: Current trends and future perspectives.
Paul G Hunter, Fiona A Chapman, Neeraj Dhaun. Br J Clin Pharmacol 2021
1